Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Note: Discounted Earnings model is only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, result may not be accurate due to the low predictability of business and the data will not be stored into our database.
Consun Pharmaceutical Group's Margin of Safety % (DCF Earnings Based) using Discounted Earnings model is
62.87%.
Consun Pharmaceutical Group Margin of Safety % (DCF Earnings Based) Related Terms
FRA:C1P vs ZTS, UTHR: Margin of Safety % (DCF Earnings Based) Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Consun Pharmaceutical Group's Margin of Safety % (DCF Earnings Based), along with its competitors' market caps and Margin of Safety % (DCF Earnings Based) data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Consun Pharmaceutical Group Margin of Safety % (DCF Earnings Based) vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Consun Pharmaceutical Group's Margin of Safety % (DCF Earnings Based) distribution charts can be found below:
* The bar in red indicates where Consun Pharmaceutical Group's Margin of Safety % (DCF Earnings Based) falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
The intrinsic value is calculated from the Discounted Earnings model with default parameters. The calculation method is the same as Discounted Cash Flow model except earnings are used in the calculation instead of free cash flow.
What does a Margin of Safety % (DCF Earnings Based) of 62.87% mean?
Consun Pharmaceutical Group (FRA:C1P) has a Margin of Safety % (DCF Earnings Based) of 62.87% as of Jul. 21, 2026. Margin of Safety % (DCF Earnings Based) is the percent difference between the current price and the intrinsic DCF Earnings price. View historical data on Consun Pharmaceutical Group.
Is Consun Pharmaceutical Group's Margin of Safety % (DCF Earnings Based) too high?
Consun Pharmaceutical Group's current Margin of Safety % (DCF Earnings Based) is 62.87%. Overall, Consun Pharmaceutical Group has a GF Score™ of 78/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Consun Pharmaceutical Group's Margin of Safety % (DCF Earnings Based) compare to ZTS and UTHR?
Consun Pharmaceutical Group's Margin of Safety % (DCF Earnings Based) of 62.87% can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Margin of Safety % (DCF Earnings Based) for a Drug Manufacturers company?
A good Margin of Safety % (DCF Earnings Based) depends on the Drug Manufacturers industry context. However, Margin of Safety % (DCF Earnings Based) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Margin of Safety % (DCF Earnings Based) mean?
A high Margin of Safety % (DCF Earnings Based) can signal that a stock is expensive relative to its fundamentals. Margin of Safety % (DCF Earnings Based) is the percent difference between the current price and the intrinsic DCF Earnings price. View historical data on Consun Pharmaceutical Group. Consun Pharmaceutical Group's current Margin of Safety % (DCF Earnings Based) is 62.87%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Consun Pharmaceutical Group stock overvalued right now?
Based on GuruFocus' analysis, Consun Pharmaceutical Group (FRA:C1P) is currently considered Significantly Overvalued. The stock's GF Value™ is €0.92, compared to a current price of €1.50 — trading 63% above its estimated fair value. The current Margin of Safety % (DCF Earnings Based) is 62.87%. Consun Pharmaceutical Group's overall GF Score™ is 78/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Margin of Safety % (DCF Earnings Based) calculated?
Margin of Safety % (DCF Earnings Based) is calculated from a company's financial statements. For Consun Pharmaceutical Group (FRA:C1P), the current Margin of Safety % (DCF Earnings Based) is 62.87% as of Jul. 21, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Consun Pharmaceutical Group (FRA:C1P) Overvalued in 2026?
Based on GuruFocus' analysis, Consun Pharmaceutical Group stock appears to be overvalued.
The current stock price of €1.50 is trading 63% above its estimated GF Value™ of €0.92.
GuruFocus considers Consun Pharmaceutical Group to be Significantly Overvalued.
Key valuation signals for FRA:C1P:
Margin of Safety % (DCF Earnings Based): 62.87%
GF Value™: €0.92 vs. price of €1.50 (63% above fair value)
No single metric tells the full story. See the FRA:C1P stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Consun Pharmaceutical Group Ltd is a biotechnology company with a modern pharmaceutical enterprise that integrates R&D, production, and marketing. The company has two reportable segments: the Consun pharmaceutical segment, which is the key revenue driver, and makes and sells modern Chinese medicines and medical contrast medium, and the Yulin pharmaceutical segment, which manufactures and sells traditional Chinese medicines. Company derives revenue from kidney medicines, contrast mediums, orthopedics medicines, dermatologic medicines, hepatobiliary medicines, medicines for women and children, and others.
78GF Score
Get the complete analysis for FRA:C1P
Margin of Safety % (DCF Earnings Based) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:C1P has been successfully added to your 
